|
|
Article: IL13-PE38QQR study commences in malignant glioma patient at initial diagnosis.
- Article from:
- Obesity, Fitness & Wellness Week
- Article date:
- September 4, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 SEP 4 - (NewsRx.com & NewsRx.net) -- NeoPharm, Inc., (NEOL) announced that the first patient in a new phase I clinical trial of its tumor-targeting compound, IL13-PE38QQR, for the treatment of malignant glioma at initial diagnosis, has been treated at the Cleveland Clinic.
IL13-PE38QQR is being administered via convection-enhanced delivery (CED) following tumor resection after initial diagnosis, using catheters placed directly in the brain near the tumor resection site.
"We are pleased that enrollment has begun in this phase I trial of IL13-PE38QQR for the treatment of malignant glioma at initial diagnosis," said Greg Young, NeoPharm's president and ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cleveland Clinic Seeks Highly Motivated Individuals ...
PR Newswire Europe;
January 22, 2007 ;
700+ words
... ... The world's leading heart center, Cleveland Clinic, exhibits at Arab Health for first time and recruits employees for future hospital, Cleveland Clinic Abu Dhabi Cleveland Clinic, one of the world's leading healthcare ...
|
|